The N-dechloroethylation of ifosfamide: Using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 4, 1996, Pages 332-336

  Wainer, Irving W ^a,c   Ducharme, Julie ^a   Granvil, Camille P ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Ifosfamide enantiomers; Microsomal metabolism; N dechloroethylation

Indexed keywords

DRUG METABOLITE; IFOSFAMIDE; MESNA;

ARTICLE; BIOTRANSFORMATION; CLINICAL ARTICLE; CLINICAL TRIAL; DECHLORINATION; DRUG URINE LEVEL; ENANTIOMER; FEMALE; GAS CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY PELVIS CARCINOMA; MASS SPECTROMETRY; NEUROTOXICITY; PRIORITY JOURNAL; STEREOSPECIFICITY; URINARY EXCRETION;

ADULT; BIOTRANSFORMATION; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; PELVIC NEOPLASMS; RECURRENCE; STEREOISOMERISM;

EID: 0030071188     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050393     Document Type: Article

References (17)

1. Allen LM, Creaven PJ (1972) In vitro activation of isophosphamide (NSC-109724). A new oxazaphosphorine by rat liver microsomes. Cancer Chemother Rep 56:603-610
2. Boos J, Welslau U, Ritter J, Blaschke G, Scellong G (1990) Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother Pharmacol 28:455-460
3. Brade WP, Herdrich K, Varini M (1985) Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat Rev 12:1-47
4. Chang TKH, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629-5637
5. Colvin M (1982) The comparative pharmacology of cyclophosphamide and ifoslamide. Semin Oncol 9 [Suppl 1]: 2-7
6. Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M (1973) Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol 23:115-129
7. Crom WR, Kearns CM, Wainer IW, Meyer WH, Pratt CB, Heideman RL, Relling MV (1991) Urinary excretion of ifosfamide enantiomers in children with cancer. Clin Pharmacol Ther 49:1952
8. Goren MP, Wright RK, Pratt CB, Pell PE (1986) Dechloroethylation of ifosfamide and neurotoxicity. Lancet ii:1219
9. Granvil CP, Gerhreke B, König WA, Wainer IW (1993) The determination of the enantiomers of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in plasma and urine using enantioselective gas chromatography with mass spectrometric detection. J Chromtogr 622:21-31
10. Granvil CP, Ducharme J, Leyland-Jones B, Trudeau M, Wainer IW (1996) Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients. Cancer Chemother Pharmacol, 37:451-456
11. Lewis LD, Meanwell CA (1990) Ifosfamide pharmacokinetics and neurotoxicity. Lancet 335:175
12. Lewis LD, Fitzgerald DL, Mohan P, Harper PG, Rogers HJ (1990) Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 30:725-732
13. Lewis LD, Fitzgerald DL, Mohan P, Thatcher PG, Roger HJ (1991) The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. Br J Clin Pharmacol 31:77-82
14. Lind MJ, Roberts HL, Thatcher N, Idle JR (1990) The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 26: 105-111
15. Misiura K, Okruszek A, Pankiewicz K, Stec WJ, Czownicki Z, Utracka B (1983) Stcreospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine. J Med Chem 26:674-679
16. Wainer IW, Ducharme J, Granvil CP, Trudeau M, Leyland-Jones B, (1994) Ifosfamide stereoselective dechloroethylation and neurotoxicity. Lancet 383:982-983
17. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Baune PH, Idle JR (1994) Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 47:1157-1161